2018

JERUSALEM, Dec. 6, 2018 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that the Accordion Pill™ developed for a proprietary Novartis compound is continuing into a clinical PK study under the previously announced Feasibility and Option agreement with Novartis Pharmaceuticals. Following achievement of the required in-vitro specifications, the companies are […]

by

Knee arthroscopy surgeons, perhaps unwittingly, participated in opioid creep with their patients in the years from 2004 to 2012. In a study published online by the Journal of the American Medical Association (JAMA), Hannah Wunsch, M.D., M.Sc., of Sunnybrook Health Sciences Centre, Toronto, and colleagues assessed trends in the amount of hydrocodone/acetaminophen and oxycodone/acetaminophen prescribed […]

by

The cannabidiol marketplace is likely to witness significant RD investment in the pharmaceutical industry as a broad-spectrum pharmaceutical therapeutics. Multiple scientific studies have shown promising results of cannabidiol for its potential in the treatment of a number of diseases. Following which the Cannabidiol Market is marked by a considerable cannabidiol therapeutics getting FDA approval or […]

by

Save Article Revive Therapeutics Ltd. (TSXV:RVV), a cannabinoid biopharma stock, jumped after receiving an orphan drug designation for the treatment of autoimmune hepatitis Sean Mason | June 27, 2018 | SmallCapPower A U.S. Food and Drug Administration designation was good news for investors in a cannabinoid biopharma stock Wednesday. Here’s some small stocks making big moves on Wednesday, June […]

by

Epidiolex, GW Pharmaceuticals’ investigational cannabis-based oral therapy, was proven safe in a Phase 2 clinical trial testing it in young children with Dravet syndrome. The therapy is a plant-derived cannabidiol being developed for patients with treatment-resistant forms of epilepsy including Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. Data on the Phase 2 CARE1 trial (NCT02091206) were […]

by

-Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’s potential within the field of epilepsy- LONDON and CARLSBAD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company […]

by

The US Food and Drug Administration (FDA) has permitted marketing for the Brainsway Deep Transcranial Magnetic Stimulation System, a device designed to treat patients with obsessive compulsive disorder (OCD). Transcranial magnetic stimulation (TMS), a procedure that stimulates nerve cells in the brain through magnetic fields, was originally permitted marketing as a major depression therapy in […]

by

The US Food and Drug Administration’s (FDA) review of post-marketing reports have confirmed that pimavanserin (Nuplazid) is not associated with any new or unexpected safety findings that link the drug to patient deaths and serious adverse events (SAEs). The FDA’s review concludes a five-month speculation which began when CNN reported the Acadia Pharmaceutical antipsychotic therapy […]

by

Jette Frederiksen, MD An extensive review found no evidence linking vaccines to the onset of multiple sclerosis (MS), and while there is a possible risk for relapse after live yellow fever vaccine, vaccinations were deemed generally safe and effective in preventing the infections that have increased risk of relapse. Jette Frederiksen, MD, Professor, Department of […]

by

The US Food and Drug Administration (FDA) approved galcanezumab (Emgality) for the preventive treatment of migraine in adults. The 120 mg dose is offered as a once-monthly, self-administered, subcutaneous injection in either pen or syringe forms. “Despite the devastating impact of migraine, only about 10% of people living with the disease are currently taking a […]

by

The US Food and Drug Administration (FDA) has approved Aquestive Therapeutics’ clobazam (SYMPAZAN) oral film for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years or older. This approval marks the first and only oral film approved by the FDA for the treatment of seizures associated with Lennox-Gastaut Syndrome. “Treating […]

by

GM saves 2,700 jobs General Motors’ plans to lay off 14,000 salaried and blue-collar workers might not be as bad as originally projected. The company said Friday that 2,700 out of the 3,300 U.S. factory jobs slated for elimination will now be saved. Blue-collar workers will still lose jobs at four U.S. plants slated for […]

by